Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core Growth Allocation ETF (AOR) vs Cassava Sciences Inc (FLNA) Price & Performance

iShares Core Growth Allocation ETF
Cassava Sciences Inc

Price performance

Price movement over the last 24 hours

Key statistics

iShares Core Growth Allocation ETF vs Cassava Sciences Inc — how do they compare? iShares Core Growth Allocation ETF trades at $69.09, while Cassava Sciences Inc trades at $1.18 (market cap $57.49M). The key difference: iShares Core Growth Allocation ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

AORFLNA
52-Week High
$69.85$4.64
52-Week Low
$61.00$1.16
Market Cap
$57.49M
Sector
Health
Enterprise Value
-$29.09M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core Growth Allocation ETF

The iShares Core Growth Allocation ETF (AOR) trades at $69.10, up 0.25% on the day, with a bearish technical signal from moving averages and neutral oscillators. The fund maintains a fixed 60/40 stock/bond allocation, rebalanced semiannually, with a low 0.20% expense ratio. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.

Outlook: AOR offers diversified, low-cost exposure but faces headwinds from equity-bond correlation shifts. Risks include interest rate sensitivity and competition from pure equity funds. Analyst sentiment is mixed, balancing simplicity against relative returns.

Cassava Sciences Inc

FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.

While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core Growth Allocation ETF

The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.

Read more on AOR

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA